Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002 for Bristol-Myers Squibb Company. The company operates in three reportable segments: Pharmaceutical Group, Nutritional Group, and Other Healthcare. The reporting period reflects the integration of the DuPont Pharmaceuticals acquisition (completed October 2001) and significant adjustments related to U.S. wholesaler inventory levels and rebate accruals.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $4,082 million | $4,689 million |
| Net Earnings | $585 million | $1,336 million |
| Earnings Per Share (Diluted) | $0.30 | $0.68 |
| Operating Cash Flow | ($1,086 million) used | $869 million provided |
| Cash and Equivalents | $3,382 million | $2,634 million |
| Total Debt (Short + Long Term) | $6,478 million | N/A (Not explicitly totaled in text) |
| Working Capital | $3,133 million | N/A |
Note: Total Debt calculated as Short-term borrowings ($308M) + Long-Term Debt ($6,170M). Working Capital calculated as Current Assets ($9,940M) - Current Liabilities ($6,807M).
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 13% year-over-year. Excluding a $262 million rebate adjustment, sales decreased 7%. The decline was driven by a 4% volume decrease, 2% foreign exchange impact, and 1% price reduction (notably on TAXOL* due to generic competition).
- Earnings Drop: Net earnings fell 56% to $585 million. Earnings before income taxes dropped 57% to $718 million.
- Cash Flow Reversal: Operating cash flow swung from a positive $869 million in Q1 2001 to a negative $1,086 million in Q1 2002. This was primarily due to $1,627 million in income tax payments related to the prior year's sale of the Clairol business.
- Segment Performance:
- Pharmaceuticals: Sales down 17% to $3,240 million. Significant declines in GLUCOPHAGE IR, TAXOL*, and BUSPAR* due to loss of exclusivity.
- Nutritionals: Sales down 8% to $463 million.
- Other Healthcare: Sales up 34% to $379 million, driven by the inclusion of the Medical Imaging business from the DuPont acquisition.
Guidance, Outlook, and Risks
- Wholesaler Inventory Impact: Management estimates that reductions in U.S. pharmaceutical wholesaler inventories will negatively affect sales and earnings by approximately $0.40 per diluted share over the next four quarters (beginning Q2 2002).
- Nonrecurring Items: Q1 2002 results were impacted by:
- A $262 million pretax charge for Medicaid and prime vendor rebate accrual adjustments.
- A $125 million pretax litigation charge (including Watson Pharmaceutical settlement).
- A $112 million charge for acquired in-process research and development (ImClone agreement).
- A $30 million gain on the sale of two branded products.
- Product Pipeline:
- PLAVIX: FDA approved for acute coronary syndrome; guidelines updated to include it in standard therapy.
- VANLEV (Omapatrilat): OCTAVE study showed greater blood pressure reduction vs. enalapril but higher angioedema rates. OVERTURE study showed similar efficacy to enalapril for heart failure.
- Credit Rating: Moody's reduced the company's credit rating from AAA to AA in April 2002.
- Accounting Changes: The company adopted SFAS No. 142, ceasing the amortization of goodwill effective 2002, subjecting it instead to annual impairment tests.
Investor Verification Checklist
- Rebate Accrual Accuracy: Verify the $262 million adjustment regarding Medicaid and prime vendor rebates and its impact on future revenue recognition.
- Wholesaler Inventory Levels: Monitor the execution of inventory destocking and the projected $0.40 EPS impact over the next year.
- Generic Competition: Assess the long-term revenue trajectory for GLUCOPHAGE IR, TAXOL*, and BUSPAR* following the loss of exclusivity.
- ImClone Investment: Review the status of the Erbitux development and the potential for future impairment charges on the $509 million investment.
- Litigation Exposure: Track the resolution of the Watson Pharmaceutical settlement and other pending legal proceedings.